Mainz Biomed B.V. downgraded by H.C. Wainwright
$MYNZ
Biotechnology: Pharmaceutical Preparations
Health Care
H.C. Wainwright downgraded Mainz Biomed B.V. from Buy to Neutral
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/14/2025 | $14.00 | Buy | Maxim Group |
| 11/25/2024 | Buy → Neutral | H.C. Wainwright | |
| 11/21/2023 | Overweight → Neutral | Cantor Fitzgerald | |
| 6/21/2022 | $25.00 | Buy | H.C. Wainwright |
6-K - MAINZ BIOMED N.V. (0001874252) (Filer)
424B5 - MAINZ BIOMED N.V. (0001874252) (Filer)
424B3 - MAINZ BIOMED N.V. (0001874252) (Filer)
BERKELEY, Calif. and MAINZ, Germany, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today its participation in the upcoming 2025 Maxim Growth Summit, taking place October 22-23, 2025, at The Hard Rock Hotel NYC. The prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries. Keynote speakers include Larry Kudlow (Broadcaster, Fox News) and Christopher Ruddy (CEO, Newsmax Media). The conference will also feature roundtable discussions with C
Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announces positive topline results from its feasibility study, examining a non-invasive blood-based screening test for the early detection of pancreatic cancer, initiated earlier this year. The study confirmed the strong clinical accuracy and utility of licensed proprietary biomarkers from Liquid Biosciences for developing an innovative screening test for pancreatic cancer. Researchers evaluated 18 licensed biomarkers across multiple candidate panels to streamline assay complexity. The leading panel achieved 100% sensitivity and 95% specifi
BERKELEY, Calif. and MAINZ, Germany, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce its participation in the upcoming Colorectal Cancer (CRC) Screening Committee Plenary Meeting and Expert Working Group (EWG) Sessions hosted by the World Endoscopy Organization (WEO), taking place on October 3rd, 2025, in Berlin, Germany. This high-level gathering brings together global leaders in colorectal cancer screening to evaluate emerging technologies, exchange scientific insights, and help shape future strategies for early detection
Maxim Group initiated coverage of Mainz Biomed B.V. with a rating of Buy and set a new price target of $14.00
H.C. Wainwright downgraded Mainz Biomed B.V. from Buy to Neutral
Cantor Fitzgerald downgraded Mainz Biomed B.V. from Overweight to Neutral
BERKELEY, Calif. and MAINZ, Germany, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce its participation in the upcoming Colorectal Cancer (CRC) Screening Committee Plenary Meeting and Expert Working Group (EWG) Sessions hosted by the World Endoscopy Organization (WEO), taking place on October 3rd, 2025, in Berlin, Germany. This high-level gathering brings together global leaders in colorectal cancer screening to evaluate emerging technologies, exchange scientific insights, and help shape future strategies for early detection
BERKELEY, Calif. and MAINZ, Germany, April 29, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, has entered into a technology partnership with UK-based EDX Medical Group plc (AQSE: EDX), which develops innovative digital diagnostic products and services supporting personalized treatments for cancer, cardiovascular and infectious diseases. Under the agreement, EDX Medical will access Mainz Biomed's molecular diagnostic technology as part of the expansion of its portfolio of products for sale in the UK. "We are delighted to join forces with EDX Medical Limited t
BERKELEY, Calif. and MAINZ, Germany, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the addition of Petra Smeltzer Starke as a Brand Ambassador for the Company. As Brand Ambassador she will help the Company in the development and dissemination of messaging focused on the importance of early detection of colorectal cancer. "We are excited about Petra joining our team as Brand Ambassador. Her broad and deep experience will be invaluable to us as we bring our next generation colorectal cancer screening product to market, with the
Transaction entails executing option agreements to purchase IP portfolio associated with current ColoAlert product and the novel gene expression (mRNA) biomarkers being evaluated in ColoFuture/eAARLY DETECT Studies BERKELEY, Calif. and MAINZ, Germany, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the execution of its option from Uni Targeting Research AS to acquire all of the previously licensed scientific intellectual property ("IP") for its flagship product ColoAlert, a highly efficacious, and easy-to-use detection test for colorec
Potential for ColoAlert to Emerge as the Most Robust and Accurate At-home Screening Test for Colorectal Cancer Biomarkers Demonstrated Unique Ability to Identify Curable Precancerous Colonic Polyps as well as Curable Early-Stage Colorectal Cancer BERKELEY, Calif. and MAINZ, Germany, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today it has entered into a Technology Rights Agreement with Socpra Sciences Santé Et Humaines S.E.C. ("TTS") to access a portfolio of novel mRNA biomarkers for potential future integration into ColoAlert,
SC 13G/A - MAINZ BIOMED N.V. (0001874252) (Subject)
SC 13G/A - MAINZ BIOMED N.V. (0001874252) (Subject)
SC 13G - MAINZ BIOMED N.V. (0001874252) (Subject)